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Abstract
Background: Though nausea and vomiting is very common during pregnancy, no studies have investigated the
impact of this condition on the women’s daily lives in a Scandinavian population. The aim of this study was to
describe the burden of nausea and vomiting during pregnancy (NVP) on global quality of life, daily life functioning
and willingness to become pregnant again according to the severity of NVP symptoms.
Methods: This study is a cross-sectional population-based study conducted in Norway. Pregnant women and
mothers with children <1 year of age with current or prior NVP were eligible to participate. Data were collected
through an anonymous on-line questionnaire accessible from November 10th, 2014 to January 31st, 2015. Severity
of NVP was measured using the 24-h Pregnancy Unique Quantification of Emesis Scale (PUQE). Associations
between severity of NVP, daily life functioning and willingness to become pregnant again were tested using chi-
square tests. Associations with global quality of life measured in terms of the Quality of Life Scale (QOLS) were
estimated using generalized linear models and reported as unstandardized regression coefficients (β) with 95%
confidence intervals (CI).
Results: 712 women with NVP were included in the study. NVP was significantly associated with several characteristics,
including daily life functioning, quality of life and willingness to become pregnant again. The negative impact was greater
the more severe the symptoms were, although considerable adverse effects were also seen among women with mild and
moderate NVP symptoms. Over one fourth of the women with severe NVP considered terminating the pregnancy due to
NVP, and three in four considered not to get pregnant again. Severity of NVP remained significantly associated with
reduced global quality of life when adjusting for maternal characteristics and illnesses with β (95% CI) =−10.9 (−16.9, −4.9)
for severe versus mild NVP.
Conclusions: NVP as measured by PUQE had a major impact on various aspects of the women’s lives, including global
quality of life and willingness to become pregnant again.
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Background
Most pregnant women experience pregnancy-related
conditions, of which nausea and vomiting during preg-
nancy (NVP) is by far one of the most common. Nausea
affects approximately 70-80% of the pregnant popula-
tion, and additional vomiting is experienced by about
50% [1–3]. The symptoms of NVP range from mild to
severe, with hyperemesis gravidarum (HG) at the most
severe end of the scale. HG is characterised by excessive
nausea and vomiting, leading to dehydration, electrolyte
and nutritional disturbances, which often necessitates
hospitalisation [4, 5].
Given the high prevalence of NVP and its most often
self-limiting nature, health care providers may tend to
trivialise its impact [6]. Though NVP in general is not as-
sociated with increased risk of adverse pregnancy out-
comes, NVP imposes significant negative impact on the
women’s lives [7]. An extensive review of the literature
from 1999 to 2011 included 38 studies that investigated
the impact of NVP on health related quality of life and oc-
cupational, social and daily life functioning [7]. The review
concluded that NVP causes decreased quality of life, and
has adverse effects on social, occupational, and domestic
life functioning [7]. Findings indicate that the effects of
NVP are amplified with increased severity of NVP symp-
toms. Furthermore, an increased risk of comorbidity, es-
pecially with feelings of depression and heartburn and
reflux problems has been described in the literature [8]
posing an even larger burden on the women.
None of the studies included in the literature review
were conducted in Norway or any other Scandinavian
country. Cultural differences and differences between
countries with respect to health care systems could
infer that results obtained in other countries may not
apply for the Norwegian pregnant population. In
Norway there are approximately 60.000 births annu-
ally. The pregnancy care programme is free of charge.
Furthermore Norwegian employees are entitled to
sickness benefit if occupationally disabled due to own
illness. The sick leave might be full time or graded
(part time).
Previous studies have evaluated health related qual-
ity of life among women with NVP with generic
health status measures such as the Medical Outcomes
Study Short Form (SF36), SF12 (abbreviated version
of SF36), and the NVP specific NVPQOL developed
by Magee et al. [9–11]. Studies demonstrate great im-
pact of NVP on health related quality of life, with in-
creased adverse effects according to increased severity
of NVP [9, 10, 12, 13]. Effects have been found on
physical, social and emotional functioning, bodily
pain, general health perceptions, vitality and mental
health. However, health related quality of life instru-
ments are focused on health status and do not
capture how satisfied the women are with broader life
domains. In specific, independence and material well-
being are not captured in health status instruments
[14, 15]. The Quality of Life Scale (QOLS) belongs to
the global or overall quality of life tools, and is a
questionnaire measuring an individual’s overall satis-
faction with life using 16 questions covering relation-
ships and material well-being, health and functioning,
and personal, social and community commitment
[15–18].
To the best of our knowledge, no studies have been
performed with this perspective in women with NVP.
Utilisation of the QOLS among women with NVP could
be of great value in terms of obtaining a broader under-
standing of quality of life in this group. Such under-
standing is valuable in order to optimize pregnancy care
for this patient group.
The primary aim of this study was to describe the im-
pact of NVP on global quality of life as measured by
QOLS, according to the severity of NVP symptoms as
determined by PUQE. Secondary aims were to describe
the impact of NVP on daily life functioning and willing-
ness to become pregnant again according to the severity
of NVP symptoms.
Methods
This study is a cross-sectional, population-based study
[19]. Pregnant women and new mothers (women with
a child of < 1 year of age), who had experienced NVP
during their current or last pregnancy, were invited
to complete an anonymous on-line questionnaire
(Additional file 1). The questionnaire was adminis-
tered by SurveyXact and was accessible from 10th No-
vember 2014 to 31st January 2015. The questionnaire
was accessible via banners with invitations to partici-
pate in the study. Banners were posted on national
websites and social networks commonly visited by the
pregnant population and/or new mothers (“altfor-
mamma.no”, “mamma.no”, “tryggmammamedisin.no”,
“foreldre.no’s” Facebook page). The link was also
posted on a Facebook page specifically created for
this project, enabling the link to be shared on social
media.
Measures
The questionnaire included questions on maternal char-
acteristics, peak severity of NVP and comorbidity. The
impact of NVP was measured by a range of questions
about domestic, social and occupational life functioning.
The questionnaire also explored questions related to the
willingness to get pregnant again. The questionnaire was
reviewed by representatives from the Norwegian patient
organisation for hyperemesis, Hyperemesis Norge.
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Classification of NVP, severity of symptoms
NVP was measured and classified into three groups of
different severity by using the 24-h Pregnancy Unique
Quantification of Emesis Scale (PUQE) [20]. PUQE con-
sists of three items that are used to assess the severity of
NVP; the number of hours of nausea, number of epi-
sodes of retching and number of episodes of vomiting
within the last 24 h. Each item has five options which
are scored from 1 to 5 points. The PUQE-score is calcu-
lated by adding the values from each item which adds
up to a total score that ranges from 3 to 15 points. The
obtained total PUQE-score was used to classify the se-
verity of NVP into: mild ≤6 points; moderate 7–12
points; severe ≥13 points. PUQE has been validated and
a significant association between PUQE and risk of hos-
pitalisation due to severe NVP, increased healthcare
costs because of NVP, reduced well-being/QOL, and in-
ability to take iron supplements is described [21, 22]. A
Norwegian translated version of PUQE that was re-
cently validated was used in this current study [22]
and is currently recommended used in routine ante-
natal care in Norway [23]. The version was adapted
so that the women not being at the peak of their
symptoms were asked to recall the extent of their
NVP for a typical 24 h in the period with the most
severe symptoms.
Impact on domestic, social and occupational functioning
and family planning
The women were asked about how their NVP symptoms
affected their daily life. A list of potential areas NVP
could impact was developed based on previous findings
in the literature, and resulted in the first five items in-
cluded in Table 5. The women were posed five questions
about NVP’s negative impact on ability to perform do-
mestic chores, social life, relationship with partner, abil-
ity to care for children and work capacity (as shown in
Table 5), to which the women could respond “none”,
“minor”, “major”, or “not relevant”. The women were
also asked if they had been on sick leave due to NVP
(yes/no/not relevant). In addition, the women were
asked about if they ever considered terminating their
pregnancy due to their NVP symptoms and if they
considered not getting pregnant again due to NVP,
both to which the women could respond in free text
entry fields. The responses were categorised into yes,
no or unsure.
Measures of global quality of life
Global quality of life was measured by using the
Quality of Life Scale (QOLS) instrument [18]. Origin-
ally, it was developed by Flanagan to measure quality
of life among the general population [16-18]. The
QOLS explores factors such as material comforts,
health, relationships with family members and others,
participation in organisations, public affairs and
volunteering, socialising, work and personal develop-
ment [18]. The scale was later modified by Burckhardt et
al. for patients and a 16th item was added – independence,
ability to do for oneself [18, 24]. The women were asked
to rate their current level of satisfaction with the item
in question by ticking off on a seven point Likert
scale ranging from very satisfied to very dissatisfied.
The total QOLS score is calculated by adding up the
items, and ranges from a minimum of 16 to a max-
imum of 112 where higher scores indicate better glo-
bal quality of life.
The 16-item adapted version has been applied and val-
idated in numerous studies across patient groups and
cultures to gather quantitative information on quality of
life [15, 18]. Average total score for healthy populations
is approximately 90 [18]. For women in Norway the ref-
erence value for the global quality of life is a QOLS
score of 85 (SD 12.3) [14]. The mean total QOLS score
among women who reported having diseases or health
problems in the Norwegian study was 81.0 (SD 12.8)
[14]. For patients with fibromyalgia, the score ranged
from approximately 70 to 73 [18, 25, 26].
A validated translated Norwegian version was ap-
plied in this current study [27]. In the validation
study of the Norwegian version of the QOLS, internal
consistency (Cronbach's alpha) was 0.86 and 0.89 at
time 1 and 2, respectively, with a test-retest reliability
of 0.83 [27].
Potentially confounding factors
The women were asked about several socio-demographic
factors and health conditions that previously have been as-
sociated with NVP. The socio-demographic variables in-
cluded parity; maternal age; pre-pregnancy body mass
index (BMI); smoking during pregnancy; use of folic
acid; marital status; education; and working status.
The variables are categorised as presented in Table 1.
Maternal health variables included short term ill-
nesses and chronic diseases. A list of nine short term
illnesses was presented to the women who could spe-
cify which of the illnesses they had experienced dur-
ing pregnancy. These were heartburn and reflux
problems, headache, constipation, common cold, pain
in back, neck and/or pelvis, sleeping problems, urin-
ary tract infection, other infections, and “other” (that
could be specified in a free text entry field). The
number of short term illnesses was summed up and
categorised into ≤2, 3–4 and ≥5.
The women were also asked to report if they suffered
from any chronic disease such as allergy, asthma, dia-
betes (type 1 or 2), epilepsy, cardiovascular diseases,
muscle or skeletal problems, hyper-/hypothyroidism,
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depression/anxiety, migraine and “other”. For each
chronic disease they were presented, the women could
tick a box for affirmative response. The option “other”
could be specified in a free text entry field. In addition
the women were posed a question whether they had
ever experienced any feelings of depression due to NVP
while pregnant with the possibility to tick off for never,
seldom, sometimes, most of the time or always.
Table 1 Maternal characteristics according to severity of NVP as defined by PUQE
PUQEa
Total Mild Moderate Severe p-valueb
N = 712 n (%) N = 62 n (%) N = 439 n (%) N = 210 n (%)
Parity
0 previous live births 382 (53.7) 38 (61.3) 241 (54.9) 103 (49.0) 0.185
≥ 1 previous live births 327 (45.9) 24 (38.7) 197 (44.9) 106 (50.5)
Age, years
Under 25 145 (20.4) 11 (17.7) 87 (19.8) 46 (21.9) 0.443
25–29 273 (38.3) 27 (43.5) 157 (35.8) 89 (42.4)
30–39 281 (39.5) 23 (37.1) 187 (42.6) 71 (33.8)
Over 40 13 (1.8) 1 (1.6) 8 (1.8) 4 (1.9)
Body Mass Index (BMI) c
Underweight 33 (4.6) 2 (3.2) 23 (5.2) 8 (3.8) 0.615
Normal weight 421 (59.1) 44 (71.0) 253 (57.6) 124 (59.0)
Overweight 139 (19.5) 10 (16.1) 86 (19.6) 42 (20.0)
Obese 118 (16.6) 6 (9.7) 76 (17.3) 36 (17.1)
Smoking
No 684 (96.1) 61 (98.4) 422 (96.1) 200 (95.2) 0.557
Yes 27 (3.8) 1 (1.6) 16 (3.6) 10 (4.8)
Use of folic acid
Before and/or during pregnancy 673 (94.8) 57 (91.9) 419 (95.7) 197 (93.8) 0.270
No 37 (5.2) 5 (8.1) 19 (4.3) 13 (6.2)
Marital status
Married/cohabitating 661 (92.8) 55 (88.7) 408 (92.9) 197 (93.8) 0.363
Not married/cohabiting 51 (7.2) 7 (11.3) 31 (7.1) 13 (6.2)
Education d
Primary or secondary 219 (30.8) 16 (25.8) 127 (28.9) 76 (36.2) 0.230
Bachelor degree 292 (41.0) 25 (40.3) 183 (41.7) 84 (40.0)
Master degree 170 (23.9) 20 (32.3) 110 (25.1) 40 (19.0)
Other 30 (4.2) 1 (1.6) 19 (4.3) 10 (4.8)
Work situation
Student 57 (8.0) 6 (9.7) 35 (8.0) 16 (7.6) 0.458
Employed 570 (80.1) 51 (82.3) 351 (80.0) 168 (80.0)
Unemployed 53 (7.4) 1 (1.6) 32 (7.3) 19 (9.0)
Other 32 (4.5) 4 (6.5) 21 (4.8) 7 (3.3)
Abbreviations: PUQE, 24 h Pregnancy Unique Quantification of Emesis; NVP, nausea and vomiting of pregnancy; OR, odds ratio; CI, confidence interval
Numbers do not always add up due to missing numbers
aAs classified by PUQE: mild: ≤6 points; moderate: 7–12 points; severe ≥13
bChi-square test or Fisher’s exact test when expected count was less than 5. Adjusted for all other variables in the table
cBody mass index (BMI) is the weight in kilograms divided by the square of the height in metres
underweight: <18.5 kg/m2, normal weight: 18.5–24.9 kg/m2; overweight: 25.0–29.9 kg/m2, obese ≥30 kg/m2. Pre-pregnancy BMI is given
dPrimary: ≤10 years of education (the Norwegian compulsory primary + secondary school)
secondary: 11-13 years (high school/upper secondary or vocational school)
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Statistical analyses
Descriptive statistics were utilised as appropriate. The
Pearson chi-square or Fisher’s exact tests were used to
assess the relationship between the severity of NVP
(classified as mild, moderate and severe as defined by
PUQE) on domestic, social and occupational functioning
and family planning as well as socio-demographic and
maternal health characteristics.
Unadjusted generalized linear models (GLM) with
identity link function and normal distribution were
used to analyse associations between severity of NVP
(PUQE-categories) and quality of life (QOLS scores)
both in the total population and in subgroups strati-
fied according to the woman’s status at time of par-
ticipation (currently pregnant, currently pregnant and
experiencing NVP, new mother) to assess effect modi-
fication by sub-groups.
Since the women were asked about current quality of
life and it is unlikely that NVP could affect quality of life
also after birth, women who were no longer pregnant at
the time of report were excluded in further analyses re-
garding the association between NVP and QOLS to reveal
the effect of potential confounders. Firstly, unadjusted
GLM models for each potential confounder were esti-
mated. Secondly, the association between NVP and QOLS
were estimated using GLM with two different levels of ad-
justment, and the following variables were adjusted for in
each model:
Model 1: Adjustment for socio-demographic character-
istics: Age, education, parity, occupational status, marital
status, smoking during pregnancy, use of folic acid during
pregnancy and body mass index.
Model 2: Adjustment for the same variables as in
Model 1 plus additional adjustment for short term ill-
nesses (≤2/3-4/≥5) and chronic disease (yes/no).
The potential confounders were chosen based on pre-
viously reported associations with NVP or QOLS in the
literature and observed associations in the current study
population. Health related variables were added as a sep-
arate step in Model 2 to observe how the association be-
tween NVP and QOLS changed after additional
adjustment for co-morbidity.
The variables describing maternal characteristics were
entered as categorical variables classified as shown in
Table 1, with the exception of age which was entered as
a continuous variable.
The residuals were assessed for normality with satisfy-
ing result for each analysis performed, and adjusted R
square was reported for each model.
To further explore the relationship between severity of
NVP and quality of life kernel density curves for the dis-
tribution of QOLS were fitted separately for each cat-
egory of NVP including only women who were pregnant
at time of participation.
All statistical analyses were performed using Statistical
Package for the Social Sciences (SPSS) version 20.0 (IBM
SPSS Statistics 20) for Windows (SPSS, Chicago, IL, USA).
Results
Overall, 712 women with NVP completed the question-
naire and were included in the study.
The study participants were comparable to the general
Norwegian birthing population with respect to geo-
graphic region of residence, maternal age, marital status
and smoking status. A larger proportion of the study
participants, however, had a higher education (B.Sc. or
higher) than the women in the general birthing popula-
tion, 65% vs. 47%, respectively [19].
In total, 447 (62.8%) of the 712 women were pregnant
at time of participation and 265 (37.2%) were a new
mother with a child < 1 year of age. As defined by
PUQE, 62 (8.7%), 439 (61.7%) and 210 (29.5%) had mild,
moderate and severe NVP, respectively (Table 1). There
was no association between socio-demographic factors
and NVP (Table 1) or having a chronic disease and NVP
(Table 2). Severity of NVP however, was significantly as-
sociated with heartburn and reflux problems (71.9%
among women with severe NVP vs. 58.1% among
women with mild NVP) and headache (63.8% among
women with severe NVP vs. 46.8% among women with
mind NVP) (Table 2). Moreover, the more severe NVP
symptoms, the more often the women had feelings of
depression; 39.0% feeling depressed “most of the time”
among women with severe NVP vs. 4.8% among women
with mild NVP.
In the total study population, a mean QOLS-score
of 76.3 (95% CI 74.5-78.0) was found. Mean score
was found to be 80.5 (95% CI 78.5-82.5) among the
new mothers, 72.0 (95% CI 70.4-73.7) among women
who were pregnant at time of participation and 68.1
(95% CI 66.0-70.2) among women who experienced
NVP at time of participation (Table 3). Figure 1
shows the kernel density curves for the distribution
of QOLS-scores according to the three groups of
NVP severity among women that were currently preg-
nant. The distributions among women with severe
and moderate NVP were shifted downwards com-
pared to women with mild NVP.
Severity of NVP symptoms was significantly associated
with global quality of life among pregnant women and
women experiencing NVP at time of participation, but
not among the new mothers (Table 3). Lowest QOLS-
score was reported by women who were pregnant and
experienced severe NVP at the time of completing the
questionnaire (63.6, 95% CI 56.2-71.0) (Table 3).
In adjusted analyses including only pregnant women
(Table 4), increased NVP severity was significantly
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associated with reduced QOLS score after adjustment for
maternal characteristics in Model 1 with β (95% CI) =
−11.7 (−17.6, −5.7) for severe NVP compared with mild
NVP. The association was slightly reduced after adjust-
ment for short term illnesses and chronic disease in
Model 2, but was still significant with β (95% CI) = −10.9
(−16.9, −4.9).
NVP greatly interfered with the women’s daily lives
and was found to have important adverse effects on daily
life functioning (Table 5). More than 70% of the women
in the total study population experienced that NVP had
a major adverse impact on taking care of household
chores and on social life functioning. As many as 63.5%
reported that NVP had a major adverse effect on the
Table 3 Global quality of life (QOLS) according to severity of NVP among the total population and selected sub-populations of study
participants
QOLS PUQE











QOLS score 76.3 (74.5–78.0) 80.1 (75.7–84.4) 75.3 (73.7–77.0) 73.4 (71.0–75.8) 0.03
Pregnant at time of
participation (n = 447)




participation (n = 286)
QOLS score 68.1 (66.0–70.2) 73.3 (68.9–77.6) 67.0 (64.4–69.5) 63.6 (56.2–71.0) < 0.001
New mother at time
of participation (n = 264)
QOLS score 80.5 (78.5–82.5) 79.4 (72.2–86.6) 81.3 (78.8–83.8) 79.6 (75.9–83.2) 0.69
Abbreviations: QOLS, Quality of life scale; CI, confidence interval; PUQE, 24 h Pregnancy-Unique Quantification of Emesis. QOLS score among women in the general
Norwegian population was 85 [14]
aANOVA. Bold p-values indicate statistically significant differences between the groups
Table 2 Comorbidity according to NVP severity
PUQE
Total Mild Moderate Severe
N = 712 n (%) N = 62 n (%) N = 439 n (%) N = 210 n (%) p-valuea
Heartburn and reflux problems 458 (64.3) 36 (58.1) 270 (61.5) 151 (71.9) 0.02
Headache 441 (61.9) 29 (46.8) 277 (63.1) 134 (63.8) 0.04
Constipation 431 (60.5) 45 (72.6) 267 (60.8) 118 (56.2) 0.07
Common cold 274 (38.4) 25 (40.3) 175 (39.9) 73 (34.8) 0.43
Pain in back, neck or pelvic 469 (65.8) 41 (66.1) 297 (67.7) 130 (61.9) 0.35
Sleep problems 450 (63.2) 33 (53.2) 282 (64.2) 134 (63.8) 0.24
Urinary tract infection 114 (15.9) 7 (11.3) 67 (15.3) 39 (18.6) 0.33
Other 91 (12.8) 9 (14.5) 60 (13.7) 22 (10.5) 0.48
Any chronic illness 345 (48.5) 21 (33.9) 221 (50.3) 103 (49.0) 0.051
Feelings of depression due to NVP
Never 61 (8.6) 18 (29.0) 37 (8.4) 6 (2.9) <0.001
Seldom 121 (17.0) 22 (35.5) 82 (18.7) 17 (8.1)
Sometimes 323 (45.4) 19 (30.6) 211 (48.1) 93 (44.3)
Most of the time 187 (26.3) 3 (4.8) 101 (23.0) 82 (39.0)
Always 20 (2.8) 0 (0.0) 8 (1.8) 12 (5.7)
aChi-square test or Fisher’s exact test when expected count was less than 5. Bold p-values indicate statistically significant differences between the groups
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ability of care for their children, and for approximately
80% the relationship with partner was negatively affected
to some extent. Work capacity was impaired due to
NVP for most of the women, and 428 (60.1%) had been
on sick leave due to NVP. Family planning was also af-
fected, especially among women with severe symptoms
of which 75.7% of the women considered not to get
pregnant again. A total of 26.7% of the women with se-
vere symptoms considered to terminate the pregnancy
due to NVP.
Severity of NVP was significantly associated with im-
paired ability to engage in domestic, occupational and social
activities, with increased impact according to increased se-
verity (Table 5). More women with severe symptoms re-
ported major impact on the various parameters, however it
is worth noticing that a large proportion of women with
moderate symptoms reported major adverse impact on do-
mestic, social and occupational functioning.
Discussion
Several of the findings are important for clinical practice.
Global quality of life was significantly reduced according
to severity of NVP. The study also shows that NVP has
impact on daily life functioning and willingness to be-
come pregnant again. This study is the first study to as-
sess the impact of NVP on these outcomes in a
Scandinavian population.
Previous studies have found major impacts of NVP on
health related quality of life [7]. This current study also
demonstrates that NVP has adverse effects on the global
quality of life measured by the QOLS. The total QOLS
score among women who were pregnant or who experi-
enced NVP at time of participation were 72 and 68, re-
spectively. This is low compared to other populations
such as women in the general Norwegian population
with an average score of 85 [14]; patients with various
chronic diseases such as rheumatic disease groups, psor-
iasis and chronic obstructive pulmonary disease, who
score above 80 on the QOLS [18]; fibromyalgia patients
with scores around 70–73 [18, 25, 26]; and Israeli pa-
tients with posttraumatic stress disorder with a score of
61 [18]. Furthermore, we found that global quality of life
was significantly associated with the severity of NVP.
The mean total QOLS score among women with severe
NVP symptoms that were pregnant or were experiencing
NVP at time of participation was 67 and 64, respectively,
demonstrating that severe NVP affects global quality of
life to a great extent. However, when only the new
mothers were included in the analyses, no association
with severity of NVP was detected. Furthermore, the
mean QOLS score among the new mothers was above
80, and higher than for the two other sub-groups, ap-
proaching that of the general Norwegian population
[14]. This is reassuring as it may imply that the severity
of NVP experienced while pregnant does not affect qual-
ity of life after birth, and that global quality of life nor-
malises after birth for most women, despite having
suffered from severe NVP while pregnant.
We also investigated whether the inclusion of potential
confounders had an impact on the association between
NVP and QOLS for pregnant women. The adjusted ana-
lysis demonstrated that the association could not be ex-
plained by the investigated factors.
Major impact of NVP on the women’s quality of life
has also previously been demonstrated in studies from
other countries. In line with our results, the effects have
been found to be increased according to the severity of
the NVP symptoms [10, 12, 13]. Women suffering from
more severe symptoms were found to have a physical
quality of life close to that among women with breast
cancer, and a mental quality of life comparable to that
seen among women with postpartum depression [10].
In addition, this study demonstrates that NVP af-
fects the women’s daily life functioning and willing-
ness to become pregnant again. Especially for the
women with severe symptoms the adverse effects of
NVP were found to be substantial. The fact that more
than one fourth of the women with severe symptoms
reported that they had considered terminating the
pregnancy, is highly concerning. Other studies con-
ducted among women with HG report that 15% of
the women actually had terminated a pregnancy due
to the severity of their symptoms [28]. A Canadian
Fig. 1 QOLS score according to NVP severity as defined by PUQE.
The figure is based on analyses including only women pregnant at
time of participation. QOLS score among women in the general
Norwegian population was 85 [14]
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Table 4 Regression analyses for the association between severity of NVP and global quality of life controlling for demographic
variables, and comorbidity. (N = 447)
Univariate models Model 1 Model 2
Unstandardized regression
coefficients (β) (95% CI)
p-value Unstandardized regression
coefficients (β) (95% CI)
p-value Unstandardized regression
coefficients (β) (95% CI)
p-value
Severity of NVP
Mild Ref. Ref. Ref.
Moderate –7.8 (–13.3,–2.4) 0.005 –6.7 (–12.0,–1.4) 0.014 –5.9 (–11.2,–0.5) 0.032
Severe –13.1 (–19.1,–7.0) <0.001 –11.7 (–17.6,–5.7) <0.001 –10.9 (–16.9,–4.9) <0.001
Parity
0 previous live births Ref. Ref. Ref.
≥ 1 previous live births –4.7 (–7.9,–1.4) 0.005 –6.6 (–10.0,–3.1) <0.001 –6.7 (–10.2,–3.2) <0.001
Age, years 0.3 (–0.1, 0.6) 0.100 0.2 (–0.2, 0.6) 0.299 0.2 (–0.2, 0.6) 0.320
Body Mass Index (BMI) a
Underweight –4.1 0.2 –2.4 (–10.5, 5.8) 0.565 –1.7 (–9.9, 6.4) 0.677
Normal weight Ref. Ref. Ref.
Overweight –2.7 0.1 –3.6 (–7.8, 0.5) 0.087 –4.0 (–8.2, 0.1) 0.056
Obese –3.7 0.045 –5.6 (–10.1,–1.1) 0.014 –5.5 (–9.9,–1.0) 0.016
Smoking
No Ref. Ref. Ref.
Yes 2.2 (–6.4, 10.7) 0.617 6.0 (–2.5, 14.4) 0.166 5.9 (–2.5, 14.3) 0.168
Use of folic acid
No Ref. Ref. Ref.
Yes, before and/or during pregnancy 1.8 (–5.5, 9.0) 0.634 –1.4 (–8.4, 5.6) 0.696 –1.1 (–8.1, 5.9) 0.762
Marital status
Married/cohabitating Ref. Ref. Ref.
Not married/cohabiting –6.0 (–11.9,–0.1) 0.046 –6.8 (–12.6,–1.0) 0.021 –6.9 (–12.7,–1.1) 0.019
Education b
Primary or secondary –8.5 (–12.9,–4.1) <0.001 –6.1 (–11.0,–1.2) 0.014 –6.1 (–11.0,–1.2) 0.015
Bachelor degree –6.4 (–10.5,–2.3) 0.002 –5.1 (–9.2,–1.0) 0.015 –5.0 (–9.1,–0.8) 0.018
Master degree Ref. Ref. Ref.
Other –14.2 (–22.3,–6.1) 0.001 –13.0 (–21.2,–4.8) 0.002 –12.8 (–21.0,–4.6) 0.002
Work situation
Student –4.1 (–10.3, 2.1) 0.198 –2.6 (–8.8, 3.6) 0.407 –3.3 (–9.5, 2.9) 0.290
Employed Ref. Ref. Ref.
Unemployed –3.3 (–10.2, 3.6) 0.344 3.3 (–3.9, 10.5) 0.366 4.2 (–3.0, 11.4) 0.256
Other 0.9 (–6.7, 8.5) 0.815 2.9 (–4.4, 10.3) 0.436 4.4 (–3.0, 11.8) 0.245
Number of short term illnesses
≤ 2 Ref. – – Ref.
3–4 –4.2 (–8.4, 0.1) 0.056 –3.2 (–7.3, 1.0) 0.133
≥ 5 –6.2 (–10.7,–1.8) 0.007 –5.5 (–9.9,–1.1) 0.014
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study also demonstrated that termination of preg-
nancy occurs due to NVP [29].
It is also worth noting that among women with severe
symptoms, 76% reported that they considered never to get
pregnant again, 84% reported that the NVP had major ad-
verse effects on the ability to care for their children, and
43% reported major impact on the relationship with their
partner, reflecting substantial effects on family life func-
tioning. In total 94% reported major impact on their work
capacity and over 90% had been on sick leave due to NVP,
illustrating that occupational functioning is affected for
most women with severe NVP. However, considerable ad-
verse effects were also seen among women with moderate
symptoms, and even some women with mild symptoms
reported major impact on different aspects of daily life
functioning. This is in line with other studies describing
that even mild NVP affected important part of the
women’s daily lives, such as caring for children, rela-
tionship with partner, work productivity and intent
to become pregnant again [13, 30].
Our study implies that adequate management of
NVP is not only important for moderate to severe
cases, but also for mild cases. Health care providers
should perform individual assessments of the degree
of NVP and its implications on the woman’s quality
of life and daily life functioning for each woman pre-
senting with NVP.
Strengths and limitations
This study has several strengths and limitations that need
to be addressed. A conventional response rate could not
be calculated due to the web-based design of the study.
Furthermore, a self-selection bias of more motivated
women cannot be ruled out, possibly explaining the rela-
tively high proportion of women with severe NVP and
thus leading to an over-estimation of the amount of
women with severe symptoms. However, the utilisation of
the internet for recruitment purposes and collection of
data enabled a high number of women to be reached from
all over Norway. The participants in this study were
reasonably comparable to the general birthing population
in Norway, with a strikingly similar geographic spread,
with the exception of the somewhat higher rate of educa-
tion among the participants [19]. This may be due to the
high internet penetration in Norway. In total, 97% of the
women aged 16–44 in Norway use internet on a daily
basis [31], which may infer that this methodology is espe-
cially appropriate for the target population of this study.
There is an increased use of the internet for research pur-
poses [32]. Web-based recruitment has shown reasonable
validity in epidemiological studies [33, 34]. Furthermore,
the information reported in web-based questionnaires has
similar quality to that reported in paper based question-
naires [35–37].
Our results rely on the women’s accurate recall of the
consequences experienced due to NVP. As most women
were past the peak of NVP severity (94%), maternal
reporting of peak NVP severity was retrospective. This
may have introduced a risk for overestimation of the NVP
symptoms as shown by Koren et al. [38]. As women with
severe symptoms might be overrepresented, this may have
biased our results towards more severe consequences for
the group as a whole. However, as we have information
about the severity of the NVP symptoms, the results are
presented according to the severity of NVP.
Conclusion
Global quality of life was significantly reduced according to
severity of NVP. Severity of NVP was also significantly as-
sociated with negative effects on various aspects of daily life
functioning and willingness to become pregnant again.
Health care providers should be aware of the high burden
NVP represents for the women, and provide the necessary
support and care needed in each individual case. Prospect-
ive studies are needed to determine whether earlier treat-
ment of women with NVP may reduce the need for sick
leave, the risk of progression into severe symptoms and
hospitalisation and reduce the adverse effects of NVP on
the women’s lives.
Table 4 Regression analyses for the association between severity of NVP and global quality of life controlling for demographic
variables, and comorbidity. (N = 447) (Continued)
Chronic disease
No Ref. – – Ref.
Yes –2.2 (–5.5, 1.1) 0.184 –2.2 (–5.4, 1.1) 0.187
Adjusted R square 0.10 0.11
Abbreviations: Ref = reference category. Models were estimated using generalized linear models with QOLS as dependent variable, identity link function and
assuming a normal distribution of QOLS. Only women who were currently pregnant are included in the analyses. Bold p-values indicate significant differences
between the groups
aBody mass index (BMI) is the weight in kilograms divided by the square of the height in metres; underweight: <18.5 kg/m2, normal weight: 18.5–24.9 kg/m2;
overweight: 25.0–29.9 kg/m2, obese ≥30 kg/m2
underweight:
bPrimary: ≤10 years of education (the Norwegian compulsory primary + secondary school), secondary: 10–12 years (high school/upper secondary or vocational school)
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Table 5 Negative impact of NVP on daily life functioning and willingness to get pregnant again
PUQE
Totalb Mild Moderate Severe p-valuea
N = 712 n (%) N = 62 n (%) N = 439 n (%) N = 210 n (%)
1. Taking care of household
chores
No impact 29 (4.1) 14 (22.6) 14 (3.2) 1 (0.5) <0.001
Minor impact 150 (21.1) 37 (59.7) 103 (23.5) 10 (4.8)
Major impact 533 (74.9) 11 (17.7) 322 (73.3) 199 (94.8)
2. Social life
No impact 44 (6.2) 18 (29.0) 23 (5.2) 3 (1.4) <0.001
Minor impact 155 (21.8) 34 (54.8) 103 (23.5) 17 (8.1)
Major impact 513 (72.1) 10 (16.1) 313 (71.3) 190 (90.5)
3. Relationship with partner c, n=682
No impact 134 (19.6) 23 (38.3) 77 (18.2) 34 (17.1) <0.001
Minor impact 306 (44.9) 32 (53.3) 193 (45.7) 80 (40.2)
Major impact 242 (35.5) 5 (8.3) 152 (36.0) 85 (42.7)
4. Ability to care for children d, n=351
No impact 31 (8.8) 10 (32.3) 16 (7.7) 5 (4.5) <0.001
Minor impact 97 (27.6) 17 (54.8) 67 (32.2) 13 (11.6)
Major impact 223 (63.5) 4 (12.9) 125 (60.1) 94 (83.9)
5. Work capacity e, n=671
No impact 28 (4.2) 8 (13.8) 20 (4.9) 0 (0.0) <0.001
Minor impact 147 (21.9) 40 (69.0) 95 (23.2) 12 (5.9)
Major impact 496 (73.9) 10 (17.2) 294 (71.9) 191 (94.1)
6. Sick leave due to NVP f, n=649
No 221 (34.1) 50 (84.7) 153 (38.8) 18 (9.2) <0.001
Yes 428 (65.9) 9 (15.3) 241 (61.2) 178 (90.8)
7. Considered to terminate
the pregnancy due to NVP
No 608 (85.5) 62 (100.0) 393 (89.5) 153 (72.9) <0.001
Yes 100 (14.1) 0 (0.0) 44 (10.0) 56 (26.7)
Unsure 3 (0.4) 0 (0.0) 2 (0.5) 1 (0.5)
8. Consider not to get
pregnant again
No 333 (46.8) 54 (87.1) 233 (53.1) 46 (21.9) <0.001
Yes 353 (49.6) 6 (9.7) 188 (42.8) 159 (75.7)
Unsure 25 (3.5) 2 (3.2) 18 (4.1) 5 (2.4)
Abbreviations: CI, confidence interval; PUQE, 24 h Pregnancy-Unique Quantification of Emesis; NVP, nausea and vomiting of pregnancy
aChi-square test or Fisher’s exact test when expected count were less than 5. Bold p-values indicate statistically significant differences between the groups
bThe sums do not always add up to total due to missing (“not relevant”)
c3.8% responded “not relevant”
d52.3% did not have any children
e6.8% responded “not relevant”
f8.8% responded “not relevant”
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